Bank of New York Mellon Corp decreased its stake in shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,016 shares of the company’s stock after selling 1,311 shares during the period. Bank of New York Mellon Corp owned 0.25% of Accelerate Diagnostics worth $1,828,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Accelerate Diagnostics by 5.6% in the first quarter. Geode Capital Management LLC now owns 187,380 shares of the company’s stock valued at $2,692,000 after buying an additional 9,910 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Accelerate Diagnostics during the first quarter valued at about $1,019,000. Metropolitan Life Insurance Co. NY raised its position in Accelerate Diagnostics by 2.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 17,271 shares of the company’s stock valued at $248,000 after buying an additional 437 shares in the last quarter. Nuveen Asset Management LLC raised its position in Accelerate Diagnostics by 13.8% in the first quarter. Nuveen Asset Management LLC now owns 620,541 shares of the company’s stock valued at $8,917,000 after buying an additional 75,220 shares in the last quarter. Finally, Royal Bank of Canada raised its position in Accelerate Diagnostics by 12.0% in the first quarter. Royal Bank of Canada now owns 17,485 shares of the company’s stock valued at $251,000 after buying an additional 1,870 shares in the last quarter. 35.62% of the stock is currently owned by institutional investors.
Shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded down 1.57% during midday trading on Friday, hitting $26.95. 265,229 shares of the stock were exchanged. Accelerate Diagnostics Inc. has a 12 month low of $10.29 and a 12 month high of $28.50. The company’s market cap is $1.38 billion. The stock has a 50 day moving average price of $25.06 and a 200-day moving average price of $17.87.
Several equities analysts have issued reports on AXDX shares. BTIG Research reaffirmed a “buy” rating and issued a $26.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, June 15th. Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, September 19th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Accelerate Diagnostics presently has a consensus rating of “Buy” and an average price target of $25.33.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc. (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.